To the full analysis
HUTCHMED (China) stock: growth
HCMHUTCHMED (China) reported $549.96M in revenue for fiscal 2025, down 12.7% on the prior year, up 19.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.4%
per year from 2006 to 2025, per share 9.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 19.2% | 11.9% | 13.4% |
| Revenue per share | −17.1% | 7.0% | 9.7% |
| Earnings | no data | 49.9% | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $50.43M | −$9.61M | −$6.26M |
| 2007 | $65.11M | −$17.19M | −$15.83M |
| 2008 | $86.97M | −$17.76M | −$17.66M |
| 2009 | $111M | −$8.75M | $4.12M |
| 2010 | $134.51M | −$6.86M | −$28.52M |
| 2011 | $165.03M | $710.22K | −$1.1M |
| 2012 | $22.37M | $3.64M | $3.58M |
| 2013 | $45.97M | $5.92M | $2.53M |
| 2014 | $87.33M | −$32.82M | $9.63M |
| 2015 | $178.2M | $7.99M | −$12.71M |
| 2016 | $216.08M | $11.7M | −$13.9M |
| 2017 | $241.2M | −$26.74M | −$13.96M |
| 2018 | $214.11M | −$74.81M | −$39.21M |
| 2019 | $204.89M | −$106.02M | −$89.48M |
| 2020 | $228.37M | −$125.95M | −$81.65M |
| 2021 | $356.13M | −$194.65M | −$220.98M |
| 2022 | $426.41M | −$360.84M | −$305.26M |
| 2023 | $838M | $100.78M | $186.65M |
| 2024 | $630.2M | $37.73M | −$17.44M |
| 2025 | $549.96M | $458.12M | −$88.81M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.